| |
| |
| Celerion
is the privately owned CRO formed through the acquisition
of the development and regulatory services consultancy
and early clinical development operations of MDS Pharma
Services. |
| |
Celerion is derived
from the Latin “celeritas” meaning
swiftness and speed. This word reflects one of
our founding principles: to deliver services
that enable clients to get products to market
faster. |
|
|
The focus of the company
is providing comprehensive early clinical research
and bioanalytical services to the drug development
community. Although the name of the company is new,
Celerion is committed to the same level of service
excellence on which MDS Pharma Services built its reputation.
|
|
Celerion is derived
from the Latin “celeritas” meaning swiftness
and speed. This word reflects one of our founding
principles: to deliver services that enable clients
to get products to market faster. It also underlies
another key goal of the business: to assist clients
in making informed go/no-go decisions on compounds
in development as early as possible.
Celerion’s combination of experienced people,
scientific excellence and state-of-the-art facilities
strongly positions the company as an industry leader
in the conduct of early clinical research and bioanalysis
studies. Our breadth of service offerings include:
- Clinical Research (first-in-man to proof-of-concept
for healthy subjects and patients)
- Clinical Pharmacology Scientific Services (Modeling
and Simulation, Study Design and Protocol Development,
Data Management, Biostatistics, PK/PD, Medical
Writing and Reporting)
- Bioanalytical Services (Discovery through late
stage)
- Early Cardiac Safety Services
- Program Management
- Regulatory Affairs
- Drug Development Consultancy
|
|
Our operations are strategically located in:
- Lincoln, Nebraska
- King of Prussia, Pennsylvania
- Neptune, New Jersey
- Phoenix, Arizona
- Belfast, Northern Ireland
- Zurich, Switzerland
- Richmond, Virginia
- Quebec, Canada
|
|
|
|
